Celldex Therapeutics, Inc.
CLDX· Nasdaq
CLDXCelldex Therapeutics, Inc.
Who holds Celldex Therapeutics, Inc., from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Versant Capital Management, Inc | 689 | ±0% | $22.3K | 0.1% | Oct 2, 2026 |
